Last reviewed · How we verify

NCT03690518: QUALIREHAB

Rehabilitation of Adolescents and Young Adults With Congenital Heart Diseases

Completed NA Last updated 31 January 2023
What this trial tests

NA trial testing Cardiac rehabilitation in Heart Defects, Congenital in 142 participants. Completed in 12 September 2022.

Timeline
27 July 2018
Primary endpoint
12 September 2022
12 September 2022

Quick facts

Lead sponsorUniversity Hospital, Montpellier
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment142
Start date27 July 2018
Primary completion12 September 2022
Estimated completion12 September 2022
Sites17 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

Adults 13 to 25, any sex, with Heart Defects, Congenital or Adolescent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to measure the impact of a rehabilitation program in congenital cardiology in terms of health related quality of life. The orginality of the rehabilitation program consists in its design : initial hospitalizationfor a short period of time (5 days) at the rehabilitation center, followed by 11 weeks of rehabilitation at home under the supervision of a specialized sports trainer.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The molecular mechanisms of cardiac development and related diseases.
    Li Y, Du J, Deng S, Liu B, et al · · 2024 · cited 53× · PMID 39715759 · DOI 10.1038/s41392-024-02069-8
  2. Physical activity interventions for people with congenital heart disease.
    Williams CA, Wadey C, Pieles G, Stuart G, et al · · 2020 · cited 40× · PMID 33112424 · DOI 10.1002/14651858.cd013400.pub2
  3. Impact of a centre and home-based cardiac rehabilitation program on the quality of life of teenagers and young adults with congenital heart disease: The QUALI-REHAB study rationale, design and methods.
    Amedro P, Gavotto A, Legendre A, Lavastre K, et al · · 2019 · cited 39× · PMID 30616811 · DOI 10.1016/j.ijcard.2018.12.050
  4. Early hybrid cardiac rehabilitation in congenital heart disease: the QUALIREHAB trial.
    Amedro P, Gavotto A, Huguet H, Souilla L, et al · · 2024 · cited 24× · PMID 38430485 · DOI 10.1093/eurheartj/ehae085
  5. Impact of COVID-19 disease on clinical research in pediatric and congenital cardiology.
    Pommier V, Abassi H, Lavastre K, Calderon J, et al · · 2022 · cited 3× · PMID 35523633 · DOI 10.1016/j.arcped.2022.03.004

Verify or expand the search:

Other trials of Cardiac rehabilitation

Trials testing the same drug.

Other recruiting trials for Heart Defects, Congenital

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03690518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing